Clinical Trial Update: Safety Study of Natalizumab to Treat Multiple Sclerosis (MS) [Phase 1]

View source ↗

Summary

Phase 1 safety study of Natalizumab in multiple sclerosis has completed. The update highlights safety and tolerability data from this early-stage trial.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Progressive Multiple Sclerosis
• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• Tysabri (Natalizumab)

Snippet

Sponsor: Biogen | Conditions: Relapsing-Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis | Phase 1 | Status: COMPLETED